YNYale Nemerson

Yale Nemerson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yale Nemerson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Markus A. Riederer

    Preclinical Research Department, F. Hoffmann-LaRoche Ltd., Basel, Switzerland

    3 shared publications
  • Bernd Bohrmann

    From the Division of Thrombosis Research, Department of Medicine, and The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029; and F. Hoffmann La Roche Ltd, Pharma Division, Preclinical Research, Basel, Switzerland

    2 shared publications
  • Diana Bonderman

    From the Division of Thrombosis Research, Department of Medicine, and The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029; and F. Hoffmann La Roche Ltd, Pharma Division, Preclinical Research, Basel, Switzerland

    2 shared publications
  • Jacques Himber

    From the Division of Thrombosis Research, Department of Medicine, and The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029; and F. Hoffmann La Roche Ltd, Pharma Division, Preclinical Research, Basel, Switzerland

    2 shared publications
  • Juan J. Badimon

    From the Division of Thrombosis Research, Department of Medicine, and The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029; and F. Hoffmann La Roche Ltd, Pharma Division, Preclinical Research, Basel, Switzerland

    2 shared publications
  • Ursula Rauch

    From the Division of Thrombosis Research, Department of Medicine, and The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029; and F. Hoffmann La Roche Ltd, Pharma Division, Preclinical Research, Basel, Switzerland

    2 shared publications

Latest Publications

    • 1 November 2002
      • Vol. 88  (5) , 822-6

    Local shear conditions and platelet aggregates regulate the incorporation and activity of circulating tissue factor in ex-vivo thrombi.

    by Viji Balasubramanian, Oana Vele, Yale Nemerson

    The presence of thrombogenic blood-borne or circulating tissue factor (cTF) has recently been demonstrated. These observations have implicated cTF to be a key determinant of thrombus propagation by depositing on platelets in nascent thrombi. Previously, we detected cTF by detergent solubilization and addition of phospholipids. We now report the direct demonstration of TF activity in ex-vivo thrombi. Collagen-coated substrates were exposed to native blood at shear rates of 0, 650, and 2,000 s(-1) for 10 min in a modified rotating Teflon cone and plate viscometer. Substrates were then gently rinsed to remove 'loose' (unadherent) components of blood. cTF activity was measured by adding a solution containing 10 nM FVIIa, 100 nM FX, and 5 mM CaCl(2) to the substrates exposed to blood. Samples of this mixture were obtained at intervals for 30 min and the amount of Xa generated was quantified by adding a chromogenic substrate, Spectrozyme Xa, and measuring the increase in OD at 405 nm. Our studies show that a minimal amount of generated Xa (approximately 1nM) can be measured from ex-vivo thrombi. Static and shear samples generated the same amount of Xa, with the exception of blood subjected to 650 s(-1) shear. At 650 s(-1) shear rate, the amount of Xa generated reached a maximum of 4 nM at 5 min and then decreased to approximately 1 nM. Immunohistological stains and fluorescent images demonstrate the presence of cTF antigen at 650 s(-1) wall shear rate.


  • Local Shear Conditions and Platelet Aggregates Regulate the Incorporation and Activity of Circulating Tissue Factor in ex-vivo Thrombi

    by Oana Vele, Yale Nemerson, Viji Balasubramanian

    The presence of thrombogenic blood-borne or circulating tissue factor (cTF) has recently been demonstrated. These observations have implicated cTF to be a key determinant of thrombus propagation by depositing on platelets in nascent thrombi. Previously, we detected cTF by detergent solubilization and addition of phospholipids. We now report the direct demonstration of TF activity in ex-vivo thrombi. Collagen-coated substrates were exposed to native blood at shear rates of 0, 650, and 2000 s-1 for 10 min in a modified rotating Teflon cone and plate viscometer. Substrates were then gently rinsed to remove ‘loose’ (unadherent) components of blood. cTF activity was measured by adding a solution containing 10 nM FVIIa, 100 nM FX, and 5 mM CaCl2 to the substrates exposed to blood. Samples of this mixture were obtained at intervals for 30 min and the amount of Xa generated was quantified by adding a chromogenic substrate, Spectrozyme Xa, and measuring the increase in OD at 405 nm. Our studies show that a minimal amount of generated Xa (∼ 1nM) can be measured from ex-vivo thrombi. Static and shear samples generated the same amount of Xa, with the exception of blood subjected to 650 s-1 shear. At 650 s-1 shear rate, the amount of Xa generated reached a maximum of 4 nM at 5 min and then decreased to ∼1 nM. Immunohistological stains and fluorescent images demonstrate the presence of cTF antigen at 650 s-1 wall shear rate.


  • The TF:VIIa Complex: Clinical Significance, Structure-function Relationships and Its Role in Signaling and Metastasis

    by William Konigsberg, Daniel Kirchhofer, Markus A. Riederer, Yale Nemerson

    Summary: In healthy humans, blood vessel-tissue factor is found primarily in the adventitia and thus physically separated from coagulation factors, which mainly circulate in an inactive form. Following injury, TF is exposed to blood and initiates the coagulation cascade. The resulting fibrin formation is an essential part for the initial repair of vessel damage to minimize blood-loss (reviewed by (1-4). Therefore, TF may be considered to form a hemostatic sheath around blood vessels essential for hemostasis and appears to be essential for life inasmuch as no TF deficiency has been reported and TF knockout mice do not survive beyond the perinatal period.


  • Open Access

    Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor

    by Ursula Rauch, Diana Bonderman, Bernd Bohrmann, Juan J. Badimon, Jacques Himber, Markus A. Riederer, Yale Nemerson

    We describe thrombogenic tissue factor (TF) on leukocyte-derived microparticles and their incorporation into spontaneous human thrombi. Polymorphonuclear leukocytes and monocytes transfer TF+particles to platelets, thereby making them capable of triggering and propagating thrombosis. This phenomenon calls into question the original dogma that vessel wall injury and exposure of TF within the vasculature to blood is sufficient for the occurrence of arterial thrombosis. The transfer of TF+ leukocyte-derived particles is dependent on the interaction of CD15 and TF with platelets. Both the inhibition of TF transfer to platelets by antagonizing the interaction CD15 with P-selectin and the direct interaction of TF itself suggest a novel therapeutic approach to prevent thrombosis.


  • Open Access

    Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor

    by Ursula Rauch, Diana Bonderman, Bernd Bohrmann, Juan J. Badimon, Jacques Himber, Markus A. Riederer, Yale Nemerson

    We describe thrombogenic tissue factor (TF) on leukocyte-derived microparticles and their incorporation into spontaneous human thrombi. Polymorphonuclear leukocytes and monocytes transfer TF+particles to platelets, thereby making them capable of triggering and propagating thrombosis. This phenomenon calls into question the original dogma that vessel wall injury and exposure of TF within the vasculature to blood is sufficient for the occurrence of arterial thrombosis. The transfer of TF+ leukocyte-derived particles is dependent on the interaction of CD15 and TF with platelets. Both the inhibition of TF transfer to platelets by antagonizing the interaction CD15 with P-selectin and the direct interaction of TF itself suggest a novel therapeutic approach to prevent thrombosis.